09995.HKClinical•prnewswire•
RemeGen's Telitacicept (RC18) Received Orphan Drug Designation from EMA for Myasthenia Gravis
Sentiment:Positive (70)
Summary
YANTAI, China, June 17, 2025 /PRNewswire/ -- On June 16, 2025, RemeGen Co., Ltd. (RemeGen, stock symbols: 688331.SH/09995.HK) announced that telitacicept (RC18; brand name: 泰爱®) has received Orphan Drug Designation (ODD) from European Medicines Agency (EMA) for the treatment of...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 17, 2025 by prnewswire